1
|
Chavan Bhagwan S, Gupta VS, Deshmukh VV, Sardeshmukh SS, Sardeshmukh SP. Standardization and preliminary characterization of an ayurvedic stress-relieving head massage oil of Nardostachys jatamansi DC. J Ayurveda Integr Med 2024; 15:100900. [PMID: 38552438 PMCID: PMC10992859 DOI: 10.1016/j.jaim.2024.100900] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2023] [Revised: 10/04/2023] [Accepted: 02/02/2024] [Indexed: 04/07/2024] Open
Abstract
BACKGROUND Jatamansi/Nardostachys jatamansi (NJ) is an important aromatic shrub widely used by Ayurvedic practitioners for centuries due to its usefulness in intellect-enhancing (Medhya), strengthening (Balya), and skin disorders. Several classical dosage forms like hot or cold infusion, decoction, distillate, powders, etc. have been mentioned for NJ. Clinical trials of Jatamansi Oil (JO) as a head massage conducted by clinicians and therapists have shown encouraging results in de-stressing/stress management of cancer patients through head anointing treatment. OBJECTIVE Such effective proprietary formulation needs assessment of its characteristics using modern analytical technologies to comprehend the Ayurvedic concept of dermal pharmacology. MATERIALS AND METHODS Triplicate batches of JO were prepared by evaporating its decoction in sesame oil (SO). Basic physicochemical analysis of the raw material, in-process samples, and finished products was carried out to develop a monograph. Further, raw SO and finished product JO were subjected to TLC, and extracted in hexane and dichloromethane separately for Gas Chromatography-Mass Spectrometry (GC-MS) analysis to profile several bioactive molecules from NJ in the final product, JO. RESULTS Standard Operating Procedure was developed and a basic monograph was prepared for JO. GC-MS analysis revealed several phytocompounds dissolved/dispersed in SO after processing, while 18 additional distinct peaks were observed in JO as compared to SO. CONCLUSION This preliminary analysis supports the Ayurvedic concept of lipid-based formulations. The plausible phytocompounds anticipated based on retention times can be further quantified and studied for their probable action as anointing treatment. A detailed experimental strategy for understanding the phytochemical changes during the entire process needs to be planned and performed.
Collapse
Affiliation(s)
- Sandeep Chavan Bhagwan
- Bharatiya Sanskriti Darshan Trust's Integrated Cancer Treatment and Research Centre, Wagholi, Pune, 412 207, India; Atharva Nature Healthcare Pvt Ltd, Wagholi, Pune, 412 207, India.
| | - Vidya Shrikant Gupta
- Bharatiya Sanskriti Darshan Trust's Integrated Cancer Treatment and Research Centre, Wagholi, Pune, 412 207, India
| | - Vineeta Vasant Deshmukh
- Bharatiya Sanskriti Darshan Trust's Integrated Cancer Treatment and Research Centre, Wagholi, Pune, 412 207, India
| | - Sukumar Sadanand Sardeshmukh
- Bharatiya Sanskriti Darshan Trust's Integrated Cancer Treatment and Research Centre, Wagholi, Pune, 412 207, India; Atharva Nature Healthcare Pvt Ltd, Wagholi, Pune, 412 207, India
| | - Sadanand Prabhakar Sardeshmukh
- Bharatiya Sanskriti Darshan Trust's Integrated Cancer Treatment and Research Centre, Wagholi, Pune, 412 207, India; Atharva Nature Healthcare Pvt Ltd, Wagholi, Pune, 412 207, India
| |
Collapse
|
2
|
Jadaun GPS, Rastogi S, Kumar A, Chauhan J, Sharma SK, Kumar M, Saini PK, Tiwari R, Raghuvanshi RS. Ensuring the quality of medicines in India: An update on the development, modernization, and harmonization of drug standards in the Indian Pharmacopoeia. Saudi Pharm J 2023; 31:101825. [PMID: 37965488 PMCID: PMC10641554 DOI: 10.1016/j.jsps.2023.101825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Accepted: 10/11/2023] [Indexed: 11/16/2023] Open
Abstract
India has a sparkling pharmaceutical sector that holds a distinguished place by producing and supplying high-quality and affordable medicines across the globe. Ensuring the quality and safety of the marketed medicinal products is one of the most important components of the drug regulatory framework and assessment of the quality of medicines is usually achieved by referring to the public standards of the official Pharmacopoeia. In India, the Indian Pharmacopoeia (IP) is published at regular intervals to fulfill the requirements of the Drugs and Cosmetics Act, 1940 to ensure the quality of medicines being manufactured and/or marketed in India. The present article aims to provide an overview of the history of the IP, its standards-setting process, and the current status of monographs in the 9th edition of the IP 2022. Special focus is placed on the newly added and upgraded general chapters and monographs within the IP 2022. There are a total of 223 general chapters and 3152 drug monographs available under various categories in the IP 2022. This study also highlights a total of 92 new drug monograph additions and 412 monograph revisions in the IP 2022. It is anticipated that the standards laid down in the IP 2022 will play an imperative role in delivering quality medicines to patients within and outside India.
Collapse
Affiliation(s)
- Gaurav Pratap Singh Jadaun
- Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Sector 23, Raj Nagar, Ghaziabad 201 002, India
| | - Shruti Rastogi
- Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Sector 23, Raj Nagar, Ghaziabad 201 002, India
| | - Amit Kumar
- Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Sector 23, Raj Nagar, Ghaziabad 201 002, India
| | - Jaishiv Chauhan
- Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Sector 23, Raj Nagar, Ghaziabad 201 002, India
| | - Surendra Kumar Sharma
- Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Sector 23, Raj Nagar, Ghaziabad 201 002, India
| | - Mukesh Kumar
- Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Sector 23, Raj Nagar, Ghaziabad 201 002, India
| | - Pawan Kumar Saini
- Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Sector 23, Raj Nagar, Ghaziabad 201 002, India
| | - Ritu Tiwari
- Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Sector 23, Raj Nagar, Ghaziabad 201 002, India
| | - Rajeev Singh Raghuvanshi
- Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Sector 23, Raj Nagar, Ghaziabad 201 002, India
| |
Collapse
|
3
|
de la Casa‐Resino I, Haro Castuera A, Casimiro Elena R, Rubio Montejano C, Carapeto García R. European legislation for veterinary medicines: Would a monograph system improve the environmental risk assessment? Integr Environ Assess Manag 2021; 17:1274-1285. [PMID: 33913607 PMCID: PMC8596546 DOI: 10.1002/ieam.4431] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/14/2020] [Revised: 12/21/2020] [Accepted: 04/15/2021] [Indexed: 05/27/2023]
Abstract
The environmental risk assessment (ERA) of veterinary medicinal products (VMPs) has been a regulatory requirement in the European Union (EU) since 1993. However, in the last few years, the potential impact of human and veterinary medicines on the environment has become a growing concern worldwide. Indeed, the legal requirements for VMPs in the EU are changing. Regulation (EU) 2019/6, which will be applied from January 28, 2022, aims to update the regulatory framework for VMPs and replaces Directive 2001/82/EC. This paper analyzes the ability of both legislations to ensure a high level of protection of the environment while authorizing VMPs. Consideration is also given to the impact on administrative burdens in both the legislations. We conclude that the Regulation improves the Directive by reducing to a certain extent the regulatory burdens for the applicants and authorities. However, the knowledge of the environmental risks of all authorized VMPs and the consistency of the assessments remain quite similar between both legislations. Nevertheless, the new Regulation proposes to examine the feasibility and applicability of an assessment system based on the critical review of properties of the active substances ("monographs") or other potential alternatives. With this in mind, two proposals (a basic and an enhanced approach) for developing a monograph system are presented and their main advantages and disadvantages are explored. Integr Environ Assess Manag 2021;17:1274-1285. © 2021 The Authors. Integrated Environmental Assessment and Management published by Wiley Periodicals LLC on behalf of Society of Environmental Toxicology & Chemistry (SETAC).
Collapse
|
4
|
Abstract
The interpretation of results on immunostained cell-block sections has to be compared with the cumulative published data derived predominantly from formalin-fixed paraffin-embedded (FFPE) tissue sections. Because of this, it is important to recognize that the fixation and processing protocol should not be different from the routinely processed FFPE surgical pathology tissue. Exposure to non-formalin fixatives or reagents may interfere with the diagnostic immunoreactivity pattern. The immunoprofile observed on such cell-blocks, which are not processed in a manner similar to the surgical pathology specimens, may not be representative resulting in aberrant results. The field of immunohistochemistry (IHC) is advancing continuously with the standardization of many immunomarkers. A variety of technical advances such as multiplex IHC with refined methodologies and automation is increasing its role in clinical applications. The recent addition of rabbit monoclonal antibodies has further improved sensitivity. As compared to the mouse monoclonal antibodies, the rabbit monoclonal antibodies have 10 to 100 fold higher antigen affinity. Most of the scenarios involve the evaluation of coordinate immunostaining patterns in cell-blocks with relatively scant diagnostic material without proper orientation which is usually retained in most of the surgical pathology specimens. These challenges are addressed if cell-blocks are prepared with some dedicated methodologies such as NextGen CelBloking™ (NGCB) kits. Cell-blocks prepared by NGCB kits also facilitate the easy application of the SCIP (subtractive coordinate immunoreactivity pattern) approach for proper evaluation of coordinate immunoreactivity. Various cell-block and IHC-related issues are discussed in detail.
Collapse
Affiliation(s)
- Vinod B Shidham
- Department of Pathology, Wayne State University School of Medicine, Karmanos Cancer Center and Detroit Medical Center, Detroit, Michigan, USA
| | - Lester J Layfield
- Department of Pathology and Anatomical Sciences, University of Missouri, One Hospital Drive, Columbia, Missouri, United States
| |
Collapse
|
5
|
Goodman JE, Mayfield DB, Becker RA, Hartigan SB, Erraguntla NK. Recommendations for further revisions to improve the International Agency for Research on Cancer (IARC) Monograph program. Regul Toxicol Pharmacol 2020; 113:104639. [PMID: 32147291 DOI: 10.1016/j.yrtph.2020.104639] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2019] [Revised: 02/03/2020] [Accepted: 02/29/2020] [Indexed: 10/24/2022]
Abstract
In 2019, the International Agency for Research on Cancer (IARC) "Preamble to the IARC Monographs" expanded guidance regarding the scientific approaches that should be employed in its monographs. These amendments to the monograph development process are an improvement but still fall short in several areas. While the revised Preamble lays out broad methods and approaches to evaluate scientific evidence, there is a lack of specificity with regard to how IARC Working Groups will conduct consistent evaluations in a standardized, objective, and transparent manner; document systematic review and evidence integration actions, and substantiate how these actions and decisions inform the ultimate classifications. Furthermore, no guidance is provided to ensure Working Groups consistently incorporate mechanistic evidence in a robust manner using a defined approach in the context of 21st century knowledge of modes of action. Nor are the conclusions of the working groups subjected to outside, independent scientific peer review. Continued improvements and modernization of the procedures for evaluating, presenting, and communicating study quality, and in the methods used to conduct and peer-review evidence-based decision making will benefit the Working Group members, the IARC Monographs Programme overall, and the international regulatory community and public who rely upon the monographs.
Collapse
Affiliation(s)
- Julie E Goodman
- Gradient, One Beacon Street, 17th Floor, Boston, MA, 02108, USA.
| | - David B Mayfield
- Gradient, 600 Stewart Street, Suite 1900, Seattle, WA, 98101, USA.
| | - Richard A Becker
- American Chemistry Council, 700 2nd Street NE, Washington, DC, 20002, USA.
| | - Suzanne B Hartigan
- American Chemistry Council, 700 2nd Street NE, Washington, DC, 20002, USA.
| | | |
Collapse
|
6
|
Smith A, Jogalekar S, Gibson A. Regulation of natural health products in Canada. J Ethnopharmacol 2014; 158 Pt B:507-510. [PMID: 24969823 DOI: 10.1016/j.jep.2014.06.037] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/14/2014] [Revised: 05/20/2014] [Accepted: 06/12/2014] [Indexed: 06/03/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE/INTRODUCTION In Canada, all natural health products (NHPs) are regulated by Health Canada (HC) under the Food and Drugs Act and the Natural Health Product Regulations. All authorized products undergo pre-market assessment for safety, efficacy and quality and the degree of pre-market oversight varies depending on the risk of the product. OVERVIEW In Canada, over 70,000 products have been authorized for sale and over 2000 sites have been licensed to produce NHPs. In the management of NHPs on the Canadian market, HC employs a number of active and collaborative methods to address the most common issues such as contamination, adulteration and deceptive or misleading advertising practices. HC is currently evolving its approaches to NHPs to recognize them as part of the larger group of health products available without a prescription. As such, the regulatory responsibility for all over-the-counter (OTC) drugs, including non-prescription drugs and NHPs, has been transferred to a single federal division. CONCLUSION As a result of this transition a number of benefits are being realized with respect to government efficiency, clarity for industry, support for new innovations and consolidated government interactions with the Canadian market.
Collapse
Affiliation(s)
- Alysyn Smith
- Natural Health Products Directorate, Health Products Food Branch, Health Canada, 2936 Baseline Road, Postal Locator 3301A, Ontario, Ottawa, Canada(1)
| | - Sumedha Jogalekar
- Natural Health Products Directorate, Health Products Food Branch, Health Canada, 2936 Baseline Road, Postal Locator 3301A, Ontario, Ottawa, Canada(1).
| | - Adam Gibson
- Natural Health Products Directorate, Health Products Food Branch, Health Canada, 2936 Baseline Road, Postal Locator 3301A, Ontario, Ottawa, Canada(1)
| |
Collapse
|
7
|
Abstract
In Europe, the legal basis for requirements for medicinal products is described in the European Pharmacopoeia (Ph. Eur.) In the European Union, the Ph. Eur. is supplemented by several guidelines issued by the European Medicines Agency. Immunological veterinary products must comply with the Ph. Eur. monograph on veterinary vaccines and the accompanying texts, as well as specific monographs. The Ph. Eur. includes monographs on canine leptospirosis and bovine leptospirosis vaccines (inactivated). Both monographs require that an immunogenicity test be performed once in the target species during the life of a vaccine. The hamster challenge test is applied for batch potency testing of canine vaccines. Alternatively, serological tests or suitable validated in vitro tests to determine the content of one or more antigenic components indicative of protection may be performed. Vaccines for use in cattle are tested in a serological test in guinea pigs. The acceptance criteria in alternative tests are set with reference to a batch of vaccine that has given satisfactory results in the immunogenicity test. At a January 2012 European workshop, the suitability of the hamster potency test was questioned and unanimous agreement was reached that moving toward complete in vitro testing is possible and should be promoted.
Collapse
Affiliation(s)
- Lukas Bruckner
- Institute of Virology and Immunology, CH-3147 Mittelhaeusern, Switzerland.
| |
Collapse
|